Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Predictive test for diabetic kidney disease receives new patent

  • In News
  • March 24, 2022
  • Samantha Freidin
Predictive test for diabetic kidney disease receives new patent

12% of global health expenditure is spent on diabetes. That equates to approximately USD $673 billion. Scarily, 1 in 2 adults with diabetes is undiagnosed. 

Diabetic kidney disease (DKD) is directly caused by diabetes, and the damage the disease does to the kidneys. It is estimated that 1 in 3 diabetics will go on to develop DKD. Left unchecked, DKD can lead to dialysis or kidney transplant. 

DKD is a silent disease, with most sufferers unaware due to the lack of symptoms. Current standard of care tests involve blood and urine analysis to check for indications of disease. 

Proteomics International Laboratories (ASX: PIQ) have developed PromarkerD, the world’s first predictive diagnostic test specifically for DKD. The test analyses the patient’s blood for three specific biomarkers that indicate the early onset of DKD. The test also takes into consideration the patient’s age, HDL-cholesterol levels and glomerular filtration rate (kidney function). PIQ’s proprietary algorithm analyses these data points and delivers a patient risk report. The test has been clinically validated with studies published in multiple leading journals confirming that it can predict DKD disease up to 4 years in advance. The test is also CE Mark registered in Europe. 

Protecting their intellectual property, PromarkerD has patented their tech in multiple jurisdictions. The Company has today announced that they’ve added India to that list, where more than 74 million people live with diabetes. As the second largest diabetic population in the world (China is the largest), PIQ already has a strong existing footprint. 

The patent complements others already held by the Company, who’s intellectual property portfolio now covers 63% of the world’s population living with diabetes. 

Dr Richard Lipscombe, Managing Director of PIQ said: “Proteomics International has strong ties to India, having operated in the country since 2004. We’ve also taken part in multiple trade visits to India, connecting with the huge Indian biotechnology and pharma sectors.

“PromarkerD can help prevent the need for renal replacement therapies such as dialysis and kidney transplant, potentially saving global healthcare systems billions of dollars a year.”

The test is yet to be FDA approved with the regulatory body advising a De Novo classification pathway to approval. 

PIQ’s share price has jumped 3.57% just one hour after market open. The Company rounded out the December quarter with $4.5 million cash at hand. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx piq
  • glomerular filtration
  • kidney disease
  • piq
  • promarkerd
  • Proteomics
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.